Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00501046 · ClinicalTrials.gov registry record · Phase 3
A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease Including Assessment of Quality of Life (EPPIC-2)
A Phase 3 study, sponsored by Tanabe Pharma Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,015
- Enrollment target
NCT00501046: Completed Phase 3 study, sponsored by Tanabe Pharma Corporation.
NCT00501046 is a Phase 3 study that has completed, run by Tanabe Pharma Corporation. The registered enrollment target is 1,015 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (31% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00501046, a Phase 3 study, has completed, sponsored by Tanabe Pharma Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,015 participants
- Enrollment target
Study Summary
1\) To evaluate the effectiveness of AST-120 (spherical carbon adsorbent) added to standard-of-care therapy in moderate to severe Chronic Kidney Disease (CKD), on time to first occurrence of any event of the triple composite outcome of initiation of dialysis, kidney transplant or doubling of serum creatinine (sCr) when compared with placebo; 2) To evaluate the safety and tolerability of long-term AST-120 therapy in patients with CKD; 3) To evaluate the effects of AST-120 versus placebo, on other measures of renal function and quality of life.
Interventions
- DRUG Placebo
- DRUG AST-120
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,015 participants |
| Start Date | 2007-07 |
| Est. Completion | 2011-10 |
| Phase | Phase 3 |
What the finished NCT00501046 record still lists
NCT00501046 is an interventional study that assigns participants to a tested intervention. Its 1,015 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (31% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00501046 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00501046 about?
NCT00501046 is a clinical study titled "A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease Including Assessment of Quality of Life (EPPIC-2)". 1\) To evaluate the effectiveness of AST-120 (spherical carbon adsorbent) added to standard-of-care therapy in moderate to severe Chronic Kidney Disease (CKD), on time to first occurrence of any event of the triple composite outcome of initiation of dialysis, kidney transplant or doubling of serum c...
What is the current status of trial NCT00501046?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,015 participants. The study started on 2007-07. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00501046?
The interventions under investigation include: Placebo (DRUG), AST-120 (DRUG).
Who is sponsoring clinical trial NCT00501046?
This trial is sponsored by Tanabe Pharma Corporation, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00501046's enrollment target sits among peer trials
1,015 294th of 2000 higher than 1,707 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06146738 · 1,015 participants
The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
- NCT06608823 · 1,016 participants · NA
ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™
- NCT06549595 · 1,018 participants · Phase 3
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
- NCT02178163 · 1,020 participants · NA
Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia